$GRBK
Green Brick Partners, Inc. Stock $grbk

$grbk Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000137367024000043 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$560.6M	$447.3M	$450.4M
YoY Change	22.87%	-1.04%	4.48%
Cost Of Revenue	$371.0M	$299.1M	$308.8M
YoY Change	18.39%	-8.67%	-3.1%
Gross Profit	$189.7M	$148.3M	$141.6M
YoY Change	32.69%	18.98%	25.94%
Gross Profit Margin	33.83%	33.14%	31.45%
Selling, General & Admin	$57.60M	$50.57M	$50.92M
YoY Change	17.01%	10.07%	14.09%
% of Gross Profit	30.37%	34.11%	35.95%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.249M	$1.126M	$1.103M
YoY Change	50.48%	49.34%	69.69%
% of Gross Profit	0.66%	0.76%	0.78%
Operating Expenses	$57.60M	$50.57M	$50.92M
YoY Change	17.01%	10.07%	14.09%
Operating Profit	$132.1M	$97.69M	$90.71M
YoY Change	40.93%	24.19%	33.74%
Interest Expense	$1.186M	$2.592M	$5.477M
YoY Change	-79.19%	-38.59%	-4.23%
% of Operating Profit	0.9%	2.65%	6.04%
Other Income/Expense, Net	$5.927M	$15.35M	$5.657M
YoY Change	23.3%	257.9%	28.28%
Pretax Income	$139.2M	$115.6M	$101.8M
YoY Change	33.55%	32.65%	30.64%
Income Tax	$23.90M	$24.80M	$21.48M
% Of Pretax Income	17.17%	21.45%	21.1%
Net Earnings	$105.4M	$83.30M	$72.30M
YoY Change	41.32%	29.79%	31.87%
Net Earnings / Revenue	18.79%	18.62%	16.05%
Basic Earnings Per Share	$2.34	$1.84
Diluted Earnings Per Share	$2.32	$1.82	$1.58
COMMON SHARES
Basic Shares Outstanding	44.93M shares	44.97M shares	45.38M shares
Diluted Shares Outstanding	45.15M shares	45.43M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.3M	$185.9M	$179.8M
YoY Change	-36.4%	4.87%	134.71%
Cash & Equivalents	$133.3M	$185.9M	$199.5M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$1.792B	$1.655B	$1.533B
Prepaid Expenses
Receivables	$14.70M	$8.630M	$10.63M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.940B	$1.850B	$1.724B
YoY Change	19.68%	18.78%	14.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.975M	$6.826M	$7.054M
YoY Change	-1.26%	74.44%	141.66%
Goodwill	$680.0K	$680.0K	$680.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$324.0K	$345.0K	$367.0K
YoY Change	-20.78%	-19.58%	-18.81%
Long-Term Investments	$36.56M	$34.70M	$84.65M
YoY Change	-55.31%	-54.97%	14.05%
Other Assets	$40.19M	$39.92M	$35.01M
YoY Change	5.61%	14.49%	5.67%
Total Long-Term Assets	$124.3M	$126.6M	$179.2M
YoY Change	-20.04%	-15.02%	18.6%
TOTAL ASSETS
Total Short-Term Assets	$1.940B	$1.850B	$1.724B
Total Long-Term Assets	$124.3M	$126.6M	$179.2M
Total Assets	$2.064B	$1.977B	$1.903B
YoY Change	16.2%	15.83%	14.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$67.98M	$53.33M	$54.32M
YoY Change	18.3%	0.89%	4.86%
Accrued Expenses	$134.9M	$122.1M	$104.4M
YoY Change	29.41%	9.32%	10.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$252.2M	$229.5M	$201.8M
YoY Change	23.05%	15.33%	4.48%
LONG-TERM LIABILITIES
Long-Term Debt	$350.4M	$349.6M	$383.0M
YoY Change	-8.13%	-8.2%	0.87%
Other Long-Term Liabilities	-$1.921M	-$2.260M
YoY Change
Total Long-Term Liabilities	$348.5M	$347.3M	$383.0M
YoY Change	-8.64%	-8.79%	0.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$252.2M	$229.5M	$201.8M
Total Long-Term Liabilities	$348.5M	$347.3M	$383.0M
Total Liabilities	$561.8M	$538.7M	$548.7M
YoY Change	-6.76%	-1.98%	0.93%
SHAREHOLDERS EQUITY
Retained Earnings	$1.162B	$1.080B	$997.0M
YoY Change	33.67%	32.01%	32.17%
Common Stock	$449.0K	$451.0K	$450.0K
YoY Change	-1.1%	-2.38%	-2.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$17.19M	$3.758M	$0.00
YoY Change		-75.52%
Treasury Stock Shares
Shareholders Equity	$1.439B	$1.383B	$1.301B
YoY Change
Total Liabilities & Shareholders Equity	$2.064B	$1.977B	$1.903B
YoY Change	16.2%	15.83%	14.93%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$105.4M	$83.30M	$72.30M
YoY Change	41.32%	29.79%	31.87%
Depreciation, Depletion And Amortization	$1.249M	$1.126M	$1.103M
YoY Change	50.48%	49.34%	69.69%
Cash From Operating Activities	$2.162M	$1.017M	-$19.36M
YoY Change	-96.1%	-99.34%	-132.62%
INVESTING ACTIVITIES
Capital Expenditures	$1.382M	$942.0K	$3.013M
YoY Change	8.73%	-40.42%	354.45%
Acquisitions
YoY Change
Other Investing Activities	-$1.793M	$62.27M	-$337.0K
YoY Change	-48.18%	-4196.38%	-61.18%
Cash From Investing Activities	-$3.175M	$61.32M	-$3.350M
YoY Change	-32.89%	-2077.52%	118.81%
FINANCING ACTIVITIES
Cash Dividend Paid		$719.0K
YoY Change		0.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-51.32M	-$51.29M	-24.00M
YoY Change	237.29%	4.27%	-23.77%
NET CHANGE
Cash From Operating Activities	2.162M	$1.017M	-19.36M
Cash From Investing Activities	-3.175M	$61.32M	-3.350M
Cash From Financing Activities	-51.32M	-$51.29M	-24.00M
Net Change In Cash	-52.33M	$11.05M	-46.70M
YoY Change	-247.35%	-89.21%	-277.39%
FREE CASH FLOW
Cash From Operating Activities	$2.162M	$1.017M	-$19.36M
Capital Expenditures	$1.382M	$942.0K	$3.013M
Free Cash Flow	$780.0K	$75.00K	-$22.37M
YoY Change	-98.56%	-99.95%	-138.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	462000	usd
CY2023Q1	us-gaap	Preferred Stock Including Additional Paid In Capital PreferredStockIncludingAdditionalPaidInCapital	47696000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	467875	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	15351000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	263545000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1114154000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	12448000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1126602000	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45096392	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45025151	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	450000	usd
CY2024Q1	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	2260000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	2328000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	451000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	71241	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3758000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2024Q1	us-gaap	Revenues Revenues	447338000	usd
CY2023Q1	us-gaap	Revenues Revenues	452061000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	299081000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	327455000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	148257000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	124606000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50570000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45945000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2592000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4221000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15354000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4290000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	115633000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	87172000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24842000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19031000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	90791000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	68141000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7490000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3961000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	83301000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	64180000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.84
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.37
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44942000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45945000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45430000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46351000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45005175	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	450000	usd
CY2023Q4	us-gaap	Preferred Stock Including Additional Paid In Capital PreferredStockIncludingAdditionalPaidInCapital	47603000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255614000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	997037000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1300704000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	17309000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1318013000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5847000	usd
CY2024Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	45560	shares
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2161000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	513000	usd
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	719000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3758000	usd
CY2024Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-400000	usd
CY2024Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	6785000	usd
CY2024Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	89141000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46032930	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	460000	usd
CY2022Q4	us-gaap	Preferred Stock Including Additional Paid In Capital PreferredStockIncludingAdditionalPaidInCapital	47696000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	259410000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	754341000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1061907000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20908000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1082815000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5233000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1976000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	567000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	719000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	15351000	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	313000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	11056000	usd
CY2023Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	66776000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46211430	shares
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	817802000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	90791000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	68141000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1126000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	754000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-66000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	146000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6365000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5499000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2592000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4221000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93270000	usd
CY2024Q1	grbk	Earnest Money Depositsand Preacquisition Costs Written Off EarnestMoneyDepositsandPreacquisitionCostsWrittenOff	5000	usd
CY2023Q1	grbk	Earnest Money Depositsand Preacquisition Costs Written Off EarnestMoneyDepositsandPreacquisitionCostsWrittenOff	10000	usd
CY2024Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	998000	usd
CY2023Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	2906000	usd
CY2024Q1	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	10718000	usd
CY2023Q1	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2002000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1968000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122108000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-49987000	usd
CY2024Q1	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	-155000	usd
CY2023Q1	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	-4380000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-7188000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2960000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-991000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1058000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17758000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17512000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	10972000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7835000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1017000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	154707000	usd
CY2024Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1695000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1520000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	63960000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	942000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1581000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61323000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3101000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	22000000	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	42000000	usd
CY2024Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	25000000	usd
CY2023Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12868000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	16000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	72000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2161000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1975000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3758000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	15351000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	719000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	719000	usd
CY2024Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	6785000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	11056000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-51291000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-49189000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11049000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	102417000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	199459000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210508000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195687000	usd
CY2024Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) as set forth in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) and applicable regulations of the Securities and Exchange Commission (“SEC”), but do not include all of the information and footnotes required for complete financial statements. The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments of a normal, recurring nature necessary to fairly state our financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024 or subsequent periods due to seasonal variations and other factors.</span></div>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes, including the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
CY2024Q1	grbk	Finished Homesand Homesunder Construction FinishedHomesandHomesunderConstruction	624461000	usd
CY2023Q4	grbk	Finished Homesand Homesunder Construction FinishedHomesandHomesunderConstruction	559488000	usd
CY2024Q1	us-gaap	Inventory Real Estate Land And Land Development Costs InventoryRealEstateLandAndLandDevelopmentCosts	1012584000	usd
CY2023Q4	us-gaap	Inventory Real Estate Land And Land Development Costs InventoryRealEstateLandAndLandDevelopmentCosts	921241000	usd
CY2024Q1	grbk	Land Held For Future Development LandHeldForFutureDevelopment	14946000	usd
CY2023Q4	grbk	Land Held For Future Development LandHeldForFutureDevelopment	48991000	usd
CY2024Q1	us-gaap	Inventory Land Held For Sale InventoryLandHeldForSale	3503000	usd
CY2023Q4	us-gaap	Inventory Land Held For Sale InventoryLandHeldForSale	3503000	usd
CY2024Q1	us-gaap	Inventory Real Estate InventoryRealEstate	1655494000	usd
CY2023Q4	us-gaap	Inventory Real Estate InventoryRealEstate	1533223000	usd
CY2024Q1	grbk	Carrying Value Of Inventory Evaluated For Impairment CarryingValueOfInventoryEvaluatedForImpairment	22300000	usd
CY2023Q4	us-gaap	Real Estate Inventory Capitalized Interest Costs RealEstateInventoryCapitalizedInterestCosts	24126000	usd
CY2022Q4	us-gaap	Real Estate Inventory Capitalized Interest Costs RealEstateInventoryCapitalizedInterestCosts	22752000	usd
CY2024Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs Incurred RealEstateInventoryCapitalizedInterestCostsIncurred	3451000	usd
CY2023Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs Incurred RealEstateInventoryCapitalizedInterestCostsIncurred	3743000	usd
CY2024Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs Cost Of Sales1 RealEstateInventoryCapitalizedInterestCostsCostOfSales1	2684000	usd
CY2023Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs Cost Of Sales1 RealEstateInventoryCapitalizedInterestCostsCostOfSales1	3648000	usd
CY2024Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs RealEstateInventoryCapitalizedInterestCosts	24893000	usd
CY2023Q1	us-gaap	Real Estate Inventory Capitalized Interest Costs RealEstateInventoryCapitalizedInterestCosts	22847000	usd
CY2024Q1	grbk	Capitalized Interest As A Percentage Of Inventory CapitalizedInterestAsAPercentageOfInventory	0.015
CY2023Q4	us-gaap	Senior Notes SeniorNotes	336207000	usd
CY2023Q1	grbk	Capitalized Interest As A Percentage Of Inventory CapitalizedInterestAsAPercentageOfInventory	0.017
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	34701000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	84654000	usd
CY2024Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-10700000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	114218000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	23474000	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	17945000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	2753000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	2045000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Preexisting Increase Decrease StandardProductWarrantyAccrualPreexistingIncreaseDecrease	198000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Preexisting Increase Decrease StandardProductWarrantyAccrualPreexistingIncreaseDecrease	633000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	1309000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	1091000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	25116000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	19532000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2260000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2328000	usd
CY2024Q1	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	2260000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	2328000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	35000000	usd
CY2024Q1	us-gaap	Senior Notes SeniorNotes	311303000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26370000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	500000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.49
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	500000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.49
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M25D
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	36135000	usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	29239000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1651000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1365000	usd
CY2024Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-400000	usd
CY2023Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-313000	usd
CY2024Q1	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	38186000	usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	30291000	usd
CY2023Q2	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	usd
CY2024Q1	us-gaap	Dividends Cash DividendsCash	700000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	92000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	33.56
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	171000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	51.73
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	147000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	44.72
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	32.97
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	115000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	43.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.49
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y6M25D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26370000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6400000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5500000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3900000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	54120000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	43148000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	16610000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12653000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7200000	usd
CY2024Q1	us-gaap	Revenue Practical Expedient Remaining Performance Obligation Description RevenuePracticalExpedientRemainingPerformanceObligationDescription	Our contracts with homebuyers have a duration of less than one year. As such, the Company uses the practical expedient as allowed under ASC 606, Revenue from Contracts with Customers, and therefore has not disclosed the transaction price allocated to remaining performance obligations as of the end of the reporting period.
CY2024Q1	us-gaap	Revenues Revenues	447338000	usd
CY2023Q1	us-gaap	Revenues Revenues	452061000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	148257000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	124606000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	115633000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	87172000	usd
CY2024Q1	us-gaap	Inventory Operative Builders InventoryOperativeBuilders	1655494000	usd
CY2023Q4	us-gaap	Inventory Operative Builders InventoryOperativeBuilders	1533223000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24800000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.215
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.218
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	83301000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	64180000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44942000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45945000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.84
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44942000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45945000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	488000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	406000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45430000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46351000	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.37
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67000	shares
CY2024Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	296000000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	322500000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2024Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	9300000	usd
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	13500000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.073
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1063000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1618000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1533000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1501000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1462000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2825000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10002000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2129000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7873000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000	usd
CY2023Q2	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	usd

Files In Submission

Name	View Source	Status
0001373670-24-000043-index-headers.html	Edgar Link	pending
0001373670-24-000043-index.html	Edgar Link	pending
0001373670-24-000043.txt	Edgar Link	pending
0001373670-24-000043-xbrl.zip	Edgar Link	pending
ex311certificationofchiefe.htm	Edgar Link	pending
ex312certificationofchieff.htm	Edgar Link	pending
ex321certificationofchiefe.htm	Edgar Link	pending
ex322certificationofchieff.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grbk-20240331.htm	Edgar Link	pending
grbk-20240331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
grbk-20240331_def.xml	Edgar Link	unprocessable
grbk-20240331_cal.xml	Edgar Link	unprocessable
grbk-20240331_lab.xml	Edgar Link	unprocessable
grbk-20240331_pre.xml	Edgar Link	unprocessable
grbk-20240331_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRBK
Green Brick Partners, Inc. Stock $grbk

2024 Q2 Form 10-Q Financial Statement

#000137367024000043 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRBK Green Brick Partners, Inc. Stock $grbk

2024 Q2 Form 10-Q Financial Statement

#000137367024000043 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRBK
Green Brick Partners, Inc. Stock $grbk